ATE361080T1 - Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine - Google Patents
Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudineInfo
- Publication number
- ATE361080T1 ATE361080T1 AT02738611T AT02738611T ATE361080T1 AT E361080 T1 ATE361080 T1 AT E361080T1 AT 02738611 T AT02738611 T AT 02738611T AT 02738611 T AT02738611 T AT 02738611T AT E361080 T1 ATE361080 T1 AT E361080T1
- Authority
- AT
- Austria
- Prior art keywords
- zidovudine
- water soluble
- lamivudine
- pharmaceutically acceptable
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960002555 zidovudine Drugs 0.000 title abstract 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title abstract 2
- 229960001627 lamivudine Drugs 0.000 title 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 2
- 159000000007 calcium salts Chemical class 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 abstract 1
- 229920002907 Guar gum Polymers 0.000 abstract 1
- 239000000665 guar gum Substances 0.000 abstract 1
- 235000010417 guar gum Nutrition 0.000 abstract 1
- 229960002154 guar gum Drugs 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2002/000110 WO2003090762A1 (en) | 2002-04-23 | 2002-04-23 | Long acting compositions comprising zidovudine and lamivudine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361080T1 true ATE361080T1 (de) | 2007-05-15 |
Family
ID=29266770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02738611T ATE361080T1 (de) | 2002-04-23 | 2002-04-23 | Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050175694A1 (de) |
| EP (1) | EP1501521B1 (de) |
| AT (1) | ATE361080T1 (de) |
| AU (1) | AU2002311622A1 (de) |
| BR (1) | BR0215707A (de) |
| CZ (1) | CZ20041117A3 (de) |
| DE (1) | DE60219965T2 (de) |
| ES (1) | ES2286258T3 (de) |
| HU (1) | HUP0500217A2 (de) |
| MX (1) | MXPA04010436A (de) |
| SK (1) | SK285383B6 (de) |
| WO (1) | WO2003090762A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE474560T1 (de) * | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| WO2009129094A2 (en) * | 2008-04-15 | 2009-10-22 | Mallinckrodt Inc. | Compositions containing antiviral compounds and methods of using the same |
| CN102488671A (zh) * | 2011-12-15 | 2012-06-13 | 合肥华方医药科技有限公司 | 一种拉米夫定控释片制剂及其制备方法 |
| MA56011A (fr) * | 2019-04-05 | 2022-04-06 | Gedea Biotech Ab | Formulation de comprimé vaginal |
| CN115813970B (zh) * | 2022-11-25 | 2024-05-07 | 深圳福山生物科技有限公司 | 一种稳定释放的营养靶向组合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
| ATE186544T1 (de) * | 1992-08-04 | 1999-11-15 | James M Dunn | Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung |
| US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
| GB9622681D0 (en) * | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| AP1659A (en) * | 1998-09-14 | 2006-09-06 | Ranbaxy Laboratories Ltd | Orally administered controlled drug delivery system providing temporal and spatial control. |
-
2002
- 2002-04-23 AU AU2002311622A patent/AU2002311622A1/en not_active Abandoned
- 2002-04-23 AT AT02738611T patent/ATE361080T1/de not_active IP Right Cessation
- 2002-04-23 SK SK5022-2004A patent/SK285383B6/sk not_active IP Right Cessation
- 2002-04-23 HU HU0500217A patent/HUP0500217A2/hu unknown
- 2002-04-23 MX MXPA04010436A patent/MXPA04010436A/es active IP Right Grant
- 2002-04-23 CZ CZ20041117A patent/CZ20041117A3/cs unknown
- 2002-04-23 DE DE60219965T patent/DE60219965T2/de not_active Expired - Fee Related
- 2002-04-23 EP EP02738611A patent/EP1501521B1/de not_active Expired - Lifetime
- 2002-04-23 US US10/512,464 patent/US20050175694A1/en not_active Abandoned
- 2002-04-23 BR BR0215707-1A patent/BR0215707A/pt not_active IP Right Cessation
- 2002-04-23 ES ES02738611T patent/ES2286258T3/es not_active Expired - Lifetime
- 2002-04-23 WO PCT/IN2002/000110 patent/WO2003090762A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR0215707A (pt) | 2005-05-03 |
| DE60219965T2 (de) | 2008-01-17 |
| SK50222004A3 (sk) | 2005-05-05 |
| MXPA04010436A (es) | 2005-05-27 |
| EP1501521B1 (de) | 2007-05-02 |
| WO2003090762A1 (en) | 2003-11-06 |
| CZ20041117A3 (cs) | 2005-04-13 |
| DE60219965D1 (de) | 2007-06-14 |
| US20050175694A1 (en) | 2005-08-11 |
| ES2286258T3 (es) | 2007-12-01 |
| HUP0500217A2 (hu) | 2005-06-28 |
| SK285383B6 (sk) | 2006-12-07 |
| AU2002311622A1 (en) | 2003-11-10 |
| EP1501521A1 (de) | 2005-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0923934T3 (da) | Modified release-matrixformulering af cefaclor og cephalexin | |
| WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| IE970588A1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| RU2333745C2 (ru) | Композиции с контролируемым высвобождением | |
| BG66095B1 (bg) | Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат | |
| RU2008113439A (ru) | Композиции с замедленным высвобождением лекарственного средства | |
| HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| RU2004137118A (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления | |
| MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
| BR9913696A (pt) | Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial | |
| CZ225596A3 (en) | Film-coated tablets of paracetamol and domperidon | |
| ATE549015T1 (de) | Pharmazeutische wirkstoffhaltige formulierung mit überzug | |
| CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
| IL174830A0 (en) | Pellets containing venlafaxine hydrochloride, pharmaceutical compositions comprising them and processes for their preparation | |
| WO2004078111A3 (en) | Extended release minocycline compositions and processes for their preparation | |
| DE60219965D1 (de) | Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine | |
| UA89349C2 (uk) | Таблетка без покриття, яка містить оланзапін, та спосіб її одержання | |
| PT1461017E (pt) | Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico | |
| WO2006053089A3 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
| NO20073850L (no) | Farmasoytisk polymersammensetning for oral kontrollert frigivelsesavlevering av terbutalinsulfat | |
| MXPA06007511A (es) | Revestimientos de granulos de farmaco que imparten resistencia a la embarradura durante la compresion mecanica. | |
| EP1765340A1 (de) | Zusammensetzung mit verzögerter freisetzung für die orale verabreichung von niacin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |